Juzina

Sitagliptin, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It helps lower elevated blood glucose levels by enhancing insulin secretion and reducing glucagon release in adults with type 2 diabetes mellitus. The drug is indicated for patients who require additional glycaemic control alongside diet, exercise and other antidiabetic agents.

GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and the product complies with EU regulatory standards. All batches are manufactured under GMP conditions.

Sitagliptin acts on the incretin pathway to improve glycaemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves overall blood glucose levels and HbA1c. - Adjunct to diet and exercise: provides additional glucose lowering when lifestyle measures are insufficient. - Combination therapy: enhances the effect of metformin, sulfonylureas or insulin in multi‑drug regimens.

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Upper respiratory infection: symptoms of cold or sinusitis.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent. - Bullous pemphigoid: rare skin blistering disorder.

Patients should be evaluated for specific risk factors before initiating therapy. - Renal function: adjust dose in patients with impaired kidney function. - Hepatic function: use with caution in liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pancreatitis: monitor for persistent abdominal pain. - Pregnancy and lactation: assess risk versus benefit before prescribing. - Store at room temperature: keep in the original container, protect from moisture and heat.

Sitagliptin may interact with other medicines, requiring monitoring or avoidance.

Major Interactions (Avoid): - Concomitant insulin secretagogues: increased risk of hypoglycaemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin plasma levels. - GLP‑1 receptor agonists: additive glucose‑lowering effect can lead to hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood glucose control. - ACE inhibitors: monitor renal function when used together. - Rifampin: may reduce sitagliptin exposure, diminishing efficacy.